Phase I Study of RO5490248 and Bevacizumab in Patients with Advanced Solid Cancers

Phase I Study of RO5490248 Alone and in Combination with Bevacizumab in Patients with Advanced Solid Cancers

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222032

Enrollment

Registered

2013-02-27

Start date

2013-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Cancers

Interventions

investigational material(s) Generic name etc : RO5490248 INN of investigational material : Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material

7.5 mg/kg, 15 mg/kg control material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investig

15 mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Performance status (PS) of 0 or 1 - Advanced or recurrent cancer that is refractory to standard treatment or for which there is no standard treatment - Sufficient major organ function

Exclusion criteria

Exclusion criteria: - Pregnant or lactating women or women who have tested positive on a pregnancy test - Current or previous history of clinically significant disease - Metastasis to the CNS or History of treatment for brain metastasis - Previous discontinuation of bevacizumab treatment due to unacceptable toxicity

Design outcomes

Primary

Measure	Time frame
Safety, Pharmacokinetics CTCAE v.4.03	—

Secondary

Measure	Time frame
Anti-tumour activity RECIST ver1.1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026